Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma

Current Eye Research

Volumn 37, Issue 1, 2012, Pages 1-11

  Shoshani, Yochai Z ^a,b   Harris, Alon ^a   Shoja, Mohammadali M ^a   Rusia, Deepam ^a   Siesky, Brent ^a   Arieli, Yoel ^a   Wirostko, Barbara ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HEBREW UNIVERSITY   (Israel)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelin; Glaucoma; Ocular blood flow; Treatment; Vascular dysregulation

Indexed keywords

AVOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PERHYDRO 1 AZEPINYLCARBONYLLEUCYL DEXTRO TRYPTOPHYL DEXTRO TRYPTOPHAN; SARAFOTOXIN S6C;

AQUEOUS HUMOR; BLOOD VESSEL REACTIVITY; DISEASE COURSE; DISEASE SEVERITY; EXPERIMENTAL MODEL; GENETIC ANALYSIS; GLAUCOMA; HISTOPATHOLOGY; IN VITRO STUDY; OPTIC NERVE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; RETINA NERVE CELL; REVIEW; TRABECULAR MESHWORK; VISUAL FIELD DEFECT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; BLOOD FLOW VELOCITY; DISEASE PROGRESSION; ENDOTHELIN-1; ENDOTHELINS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; RECEPTORS, ENDOTHELIN; RETINAL VESSELS;

EID: 83655191290     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.622849     Document Type: Review

References (127)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389-393. (Pubitemid 26158268)
2. Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-13; discussion 829. (Pubitemid 34620348)
3. Leske MC, Heijl A, Hyman L, Bengtsson B. Early Manifest Glaucoma Trial: Design and baseline data. Ophthalmology. 1999;106:2144-2153. (Pubitemid 30194238)
4. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279. (Pubitemid 36105431)
5. Musch DC, Gillespie BW, Lichter PR, Niziol LM, Janz NK; CIGTS Study Investigators. Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology. 2009;116:200-207.
6. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmology. Ophthalmol. 1998;126(4):498-505.
7. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology. 1998;105(7):1146-1164.
8. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000;130(4):429-440.
9. Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008;115:1123-1129.e3.
10. Bengtsson B, Leske MC, Hyman L, Heijl A; Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:205-209. (Pubitemid 46161799)
11. Chung HS, Harris A, Kagemann L, Martin B. Peripapillary retinal blood flow in normal tension glaucoma. Br J Ophthalmol. 1999;83:466-469. (Pubitemid 29161191)
12. Yin ZQ, Vaegan, Millar TJ, Beaumont P, Sarks S. Widespread choroidal insufficiency in primary open-angle glaucoma. J Glaucoma. 1997;6:23-32. (Pubitemid 27136307)
13. Harris A, Sergott RC, Spaeth GL, Katz JL, Shoemaker JA, Martin BJ. Color Doppler analysis of ocular vessel blood velocity in normal-tension glaucoma. Am J Ophthalmol. 1994;118:642-649. (Pubitemid 24345625)
14. Rojanapongpun P, Drance SM, Morrison BJ. Ophthalmic artery flow velocity in glaucomatous and normal subjects. Br J Ophthalmol. 1993;77:25-29. (Pubitemid 23031809)
15. Plange N, Kaup M, Arend O, Remky A. Asymmetric visual field loss and retrobulbar haemodynamics in primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2006;244:978-983. (Pubitemid 44184503)
16. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open angle glaucoma: The Egna-Neumarkt Study. Ophthalmology. 2000;107:1287-1293.
17. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol. 1995;113:216-221.
18. Drance S, Anderson DR, Schulzer M; Collaborative Normal- Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol. 2001;131:699-708. (Pubitemid 32522638)
19. Leighton DA, Phillips CI. Systemic blood pressure in openangle glaucoma, low tension glaucoma, and the normal eye. Br J Ophthalmol. 1972;56:447-453.
20. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994;117:603-624. (Pubitemid 24150730)
21. Emre M, Orgl S, Gugleta K, Flammer J. Ocular blood flow alteration in glaucoma is related to systemic vascular dysregulation. Br J Ophthalmol. 2004;88:662-666. (Pubitemid 38526650)
22. Pache M, Dubler B, Flammer J. Peripheral vasospasm and nocturnal blood pressure dipping-two distinct risk factors for glaucomatous damage? Eur J Ophthalmol. 2003;13: 260-265. (Pubitemid 37279508)
23. Flammer J, Orgl S. Optic nerve blood-flow abnormalities in glaucoma. Prog Retin Eye Res. 1998;17:267-289. (Pubitemid 28339915)
24. Thorin E, Clozel M. The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol. 2010;60:1-26.
25. Warner TD, Klemm P. What turns on the endothelins? Inflamm Res. 1996;45:51-53. (Pubitemid 26064404)
26. Fenhammar J, Andersson A, Frithiof R et al. The endothelin receptor antagonist tezosentan improves renal microcirculation in a porcine model of endotoxemic shock. Acta Anaesthesiol Scand. 2008;52:1385-1393.
27. Andersson A, Fenhammar J, Frithiof R, Weitzberg E, Sollevi A, Hjelmqvist H. Mixed endothelin receptor antagonism with tezosentan improves intestinal microcirculation in endotoxemic shock. J Surg Res. 2008;149:138-147.
28. Thaete LG, Kushner DM, Dewey ER, Neerhof MG. Endothelin and the regulation of uteroplacental perfusion in nitric oxide synthase inhibition-induced fetal growth restriction. Placenta. 2005;26:242-250. (Pubitemid 40247013)
29. Oishi Y, Nishimura Y, Tanoue Y et al. Endothelin-1 receptor antagonist prevents deterioration of left ventricular function and coronary flow reserve in brain-dead canine heart. J Heart Lung Transplant. 2005;24:1354-1361. (Pubitemid 41247822)
30. Vatter H, Zimmermann M, Tesanovic V, Raabe A, Seifert V, Schilling L. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: Effect on endothelin(B) receptor-mediated relaxation. J Neurosurg. 2005;102:1108-1114. (Pubitemid 43193981)
31. Aubert JD, Juillerat-Jeanneret L. Therapeutic potential of endothelin receptor modulators: Lessons from human clinical trials. Expert Opin Ther Targets. 2009;13:1069-1084.
32. Cioffi GA, Orgl S, Onda E, Bacon DR, Van Buskirk EM. An in vivo model of chronic optic nerve ischemia: The dosedependent effects of endothelin-1 on the optic nerve microvasculature. Curr Eye Res. 1995;14:1147-1153. (Pubitemid 26007827)
33. Sasaoka M, Taniguchi T, Shimazawa M, Ishida N, Shimazaki A, Hara H. Intravitreal injection of endothelin-1 caused optic nerve damage following to ocular hypoperfusion in rabbits. Exp Eye Res. 2006;83:629-637. (Pubitemid 43902784)
34. Iannaccone A, Letizia C, Pazzaglia S, Vingolo EM, Clemente G, Pannarale MR. Plasma endothelin-1 concentrations in patients with retinal vein occlusions. Br J Ophthalmol. 1998;82:498-503. (Pubitemid 28266419)
35. Fuchsjöger-Mayrl G, Luksch A, Malec M, Polska E, Wolzt M, Schmetterer L. Role of endothelin-1 in choroidal blood flow regulation during isometric exercise in healthy humans. Invest Ophthalmol Vis Sci. 2003;44:728-733. (Pubitemid 36159721)
36. Polak K, Petternel V, Luksch A et al. Effect of endothelin and BQ123 on ocular blood flow parameters in healthy subjects. Invest Ophthalmol Vis Sci. 2001;42:2949-2956. (Pubitemid 33035295)
37. Resch H, Karl K, Weigert G et al. Effect of dual endothelin receptor blockade on ocular blood flow in patients with glaucoma and healthy subjects. Invest Ophthalmol Vis Sci. 2009;50:358-363.
38. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415. (Pubitemid 18090241)
39. Inoue A, Yanagisawa M, Kimura S et al. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 1989;86:2863-2867. (Pubitemid 19112640)
40. Horio T, Kohno M, Takeda T. Effects of arginine vasopressin, angiotensin II and endothelin-1 on the release of brain natriuretic peptide in vivo and in vitro. Clin Exp Pharmacol Physiol. 1992;19:575-582.
41. Ohta K, Hirata Y, Imai T et al. Cytokine-induced release of endothelin-1 from porcine renal epithelial cell line. Biochem Biophys Res Commun. 1990;169:578-584. (Pubitemid 20216147)
42. Magazine HI, Srivastava KD. Thrombin-induced vascular reactivity is modulated by ETB receptor-coupled nitric oxide release in rat aorta. Am J Physiol. 1996;271:C923-C928.
43. Corder R, Carrier M, Khan N, Klemm P, Vane JR. Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S56-S58.
44. Morawietz H, Talanow R, Szibor M et al. Regulation of the endothelin system by shear stress in human endothelial cells. J Physiol (Lond). 2000;525 Pt 3:761-770. (Pubitemid 30426795)
45. Cheng TH, Shih NL, Chen SY et al. Reactive oxygen species mediate cyclic strain-induced endothelin-1 gene expression via Ras/Raf/extracellular signal-regulated kinase pathway in endothelial cells. J Mol Cell Cardiol. 2001;33:1805-1814.
46. Wort SJ, Mitchell JA, Woods M, Evans TW, Warner TD. The prostacyclin-mimetic cicaprost inhibits endogenous endothelin-1 release from human pulmonary artery smooth muscle cells. J Cardiovasc Pharmacol. 2000;36:S410-S413.
47. Hu RM, Levin ER, Pedram A, Frank HJ. Atrial natriuretic peptide inhibits the production and secretion of endothelin from cultured endothelial cells. Mediation through the C receptor. J Biol Chem. 1992;267:17384-17389.
48. Just A, Olson AJ, Falck JR, Arendshorst WJ. NO and NO-independent mechanisms mediate ETB receptor buffering of ET-1-induced renal vasoconstriction in the rat. Am J Physiol Regul Integr Comp Physiol. 2005;288:R1168-R1177. (Pubitemid 40593699)
49. Clozel M, Gray GA. Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol. 1995;26 Suppl 3:S262-S264.
50. Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J. 1995;9:1196-1204.
51. Kawanabe Y, Nauli SM. Involvement of extracellular Ca2+ influx through voltage-independent Ca2+ channels in endothelin-1 function. Cell Signal. 2005;17:911-916. (Pubitemid 40719112)
52. Shetty SS, Okada T, Webb RL, DelGrande D, Lappe RW. Functionally distinct endothelin B receptors in vascular endothelium and smooth muscle. Biochem Biophys Res Commun. 1993;191:459-464. (Pubitemid 23222658)
53. Gray GA, Lffler BM, Clozel M. Characterization of endothelin receptors mediating contraction of rabbit saphenous vein. Am J Physiol. 1994;266:H959-H966.
54. Schmetterer L, Findl O, Strenn K et al. Effects of endothelin-1 (ET-1) on ocular hemodynamics. Curr Eye Res. 1997;16:687-692. (Pubitemid 27322721)
55. Dallinger S, Dorner GT, Wenzel R et al. Endothelin-1 contributes to hyperoxia-induced vasoconstriction in the human retina. Invest Ophthalmol Vis Sci. 2000;41:864-869. (Pubitemid 30158900)
56. Sugiyama T, Mashima Y, Yoshioka Y, Oku H, Ikeda T. Effect of unoprostone on topographic and blood flow changes in the ischemic optic nerve head of rabbits. Arch Ophthalmol. 2009;127:454-459.
57. Chauhan BC, LeVatte TL, Jollimore CA et al. Model of endothelin-1-induced chronic optic neuropathy in rat. Invest Ophthalmol Vis Sci. 2004;45:144-152. (Pubitemid 38055680)
58. Sugiyama T, Moriya S, Oku H, Azuma I. Association of endothelin-1 with normal tension glaucoma: Clinical and fundamental studies. Surv Ophthalmol. 1995;39 Suppl 1:S49-S56.
59. Kaiser HJ, Flammer J, Wenk M, Lscher T. Endothelin-1 plasma levels in normal-tension glaucoma: Abnormal response to postural changes. Graefes Arch Clin Exp Ophthalmol. 1995;233:484-488.
60. Cellini M, Possati GL, Profazio V, Sbrocca M, Caramazza N, Caramazza R. Color Doppler imaging and plasma levels of endothelin-1 in low-tension glaucoma. Acta Ophthalmol Scand Suppl. 1997;224:11-13. (Pubitemid 28184902)
61. Shaw SG, Boden JP, Biecker E, Reichen J, Rothen B. Endothelin antagonism prevents diabetic retinopathy in NOD mice: A potential role of the angiogenic factor adrenomedullin. Exp Biol Med (Maywood). 2006;231:1101-1105. (Pubitemid 43845586)
62. Sakai T, Shikishima K, Matsushima M, Tsuneoka H. Endothelin-1 in ischemic optic neuropathy. Ophthalmology. 2008;115:1262. (Pubitemid 351885405)
63. Haufschild T, Prnte C, Messerli J, Flammer J. Increased endothelin-1 plasma level in young adults with retinal vascular occlusive diseases. Klin Monbl Augenheilkd. 2004;221:357-359. (Pubitemid 38807953)
64. Kuhlmann A, Amann K, Schltzer-Schrehardt U, Kruse FE, Cursiefen C. Endothelin-1 and ETA/ETB receptor protein and mRNA: Expression in normal and vascularized human corneas. Cornea. 2005;24:837-844. (Pubitemid 41400424)
65. Fernndez-Durango R, Rolln R, Mediero A et al. Localization of endothelin-1 mRNA expression and immunoreactivity in the anterior segment of human eye: Expression of ETA and ETB receptors. Mol Vis. 2003;9:103-109. (Pubitemid 38097574)
66. Wollensak G, Schaefer HE, Ihling C. An immunohistochemical study of endothelin-1 in the human eye. Curr Eye Res. 1998;17:541-545. (Pubitemid 28306510)
67. Zhang X, Clark AF, Yorio T. Interactions of endothelin-1 with dexamethasone in primary cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2003;44:5301-5308. (Pubitemid 37475402)
68. Okafor MC, Mukhopadhyay P, Delamere NA. Studies on endothelin release and Na,K transport in porcine lens. Invest Ophthalmol Vis Sci. 2002;43:790-796. (Pubitemid 34184499)
69. Narayan S, Prasanna G, Krishnamoorthy RR, Zhang X, Yorio T. Endothelin-1 synthesis and secretion in human retinal pigment epithelial cells (ARPE-19): Differential regulation by cholinergics and TNF-?. Invest Ophthalmol Vis Sci. 2003;44:4885-4894. (Pubitemid 37315305)
70. Narayan S, Brun AM, Yorio T. Endothelin-1 distribution and basolateral secretion in the retinal pigment epithelium. Exp Eye Res. 2004;79:11-19. (Pubitemid 38737378)
71. Stitt AW, Chakravarthy U, Gardiner TA, Archer DB. Endothelin-like immunoreactivity and receptor binding in the choroid and retina. Curr Eye Res. 1996;15:111-117. (Pubitemid 26045771)
72. Ripodas A, de Juan JA, Roldn-Pallars M et al. Localisation of endothelin-1 mRNA expression and immunoreactivity in the retina and optic nerve from human and porcine eye. Evidence for endothelin-1 expression in astrocytes. Brain Res. 2001;912:137-143. (Pubitemid 32800667)
73. Chakravarthy U, Douglas AJ, Bailie JR, McKibben B, Archer DB. Immunoreactive endothelin distribution in ocular tissues. Invest Ophthalmol Vis Sci. 1994;35:2448-2454. (Pubitemid 24137040)
74. Köllberg ME, Brooks DE, Gelatt KN, Garcia-Sanchez GA, Szabo NJ, Lambrou GN. Endothelin-1, nitric oxide, and glutamate in the normal and glaucomatous dog eye. Vet Ophthalmol. 2007;10 Suppl 1:46-52. (Pubitemid 350007144)
75. Roldn-Pallars M, Rolln R, Martnez-Montero JC, Fernndez-Cruz A, Bravo-Llata C, Fernndez-Durango R. Immunoreactive endothelin-1 in the vitreous humor and epiretinal membranes of patients with proliferative diabetic retinopathy. Retina (Philadelphia, Pa). 2007;27:222-235.
76. Howell GR, Macalinao DG, Sousa GL et al. Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Invest. 2011;121:1429-1444.
77. Sugiyama K, Haque MS, Okada K, Taniguchi T, Kitazawa Y. Intraocular pressure response to intravitreal injection of endothelin-1 and the mediatory role of ETA receptor, ETB receptor, and cyclooxygenase products in rabbits. Curr Eye Res. 1995;14:479-486.
78. Granstam E, Wang L, Bill A. Effects of endothelins (ET-1, ET-2 and ET-3) in the rabbit eye; role of prostaglandins. Eur J Pharmacol. 1991;194:217-223.
79. Holl G, Lakatos P, Vargha P. Immediate increase in aqueous humour endothelin 1 concentration and intra-ocular pressure after argon laser trabeculoplasty in the rabbit. Ophthalmologica. 2000;214:292-295. (Pubitemid 30339159)
80. Okada K, Sugiyama K, Haque MS, Taniguchi T, Kitazawa Y. The effects of endothelin-1 on intraocular pressure and pupillary diameter in rabbits. Jpn J Ophthalmol. 1995;39:233-241.
81. Nonoyama T, Takei K, Sato T, Miyauchi T, Goto K, Hommura S. [The effect of subconjunctival injection of endothelin-1 on intraocular pressure in the rabbit]. Nippon Ganka Gakkai Zasshi. 1995;99:1133-1139.
82. Erickson-Lamy K, Korbmacher C, Schuman JS, Nathanson JA. Effect of endothelin on outflow facility and accommodation in the monkey eye in vivo. Invest Ophthalmol Vis Sci. 1991;32:492-495.
83. Haque MS, Taniguchi T, Sugiyama K, Okada K, Kitazawa Y. The ocular hypotensive effect of the ETB receptor selective agonist, sarafotoxin S6c, in rabbits. Invest Ophthalmol Vis Sci. 1995;36:804-808.
84. Taniguchi T, Haque MS, Sugiyama K, Okada K, Nakai Y, Kitazawa Y. Effects of endothelin A and B receptors on aqueous humor dynamics in the rabbit eye. J Ocul Pharmacol Ther. 1996;12(2):123-130. (Pubitemid 26164528)
85. Wang RF, Podos SM, Serle JB, Baltatu OC. Effect of SPP 301, an endothelin antagonist, on intraocular pressure in glaucomatous monkey eyes. Curr Eye Res. 2011;36:41-46.
86. Prasanna G, Hulet C, Desai D et al. Effect of elevated intraocular pressure on endothelin-1 in a rat model of glaucoma. Pharmacol Res. 2005;51:41-50. (Pubitemid 39425072)
87. Cellini M, Versura P, Zamparini E, Bendo E, Campos EC. Effects of endothelin-1 and flunarizine on human trabecular meshwork cell contraction. Exp Biol Med (Maywood). 2006;231:1081-1084. (Pubitemid 43845582)
88. Renieri G, Choritz L, Rosenthal R, Meissner S, Pfeiffer N, Thieme H. Effects of endothelin-1 on calcium-independent contraction of bovine trabecular meshwork. Graefes Arch Clin Exp Ophthalmol. 2008;246:1107-1115.
89. Tao W, Prasanna G, Dimitrijevich S, Yorio T. Endothelin receptor A is expressed and mediates the [Ca2+]i mobilization of cells in human ciliary smooth muscle, ciliary nonpigmented epithelium, and trabecular meshwork. Curr Eye Res. 1998;17:31-38. (Pubitemid 28039665)
90. Kohmoto H, Matsumoto S, Serizawa T. Effects of endothelin- 1 on [Ca2+]i and pHi in trabecular meshwork cells. Curr Eye Res. 1994;13:197-202. (Pubitemid 24088423)
91. Stumpff F, Wiederholt M. Regulation of trabecular meshwork contractility. Ophthalmologica. 2000;214:33-53. (Pubitemid 30084879)
92. Wiederholt M. Direct involvement of trabecular meshwork in the regulation of aqueous humor outflow. Curr Opin Ophthalmol. 1998;9:46-49. (Pubitemid 28284573)
93. Choritz L, Rosenthal R, Fromm M, Foerster MH, Thieme H. Pharmacological and functional characterization of endothelin receptors in bovine trabecular meshwork and ciliary muscle. Ophthalmic Res. 2005;37:179-187. (Pubitemid 41404757)
94. Rosenthal R, Choritz L, Zorn R et al. Endothelin receptor B in trabecular meshwork. Exp Eye Res. 2007;85:482-491. (Pubitemid 47534203)
95. Clozel M, Gray GA, Breu V, Lffler BM, Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun. 1992;186:867-873.
96. Nishimura K, Riva CE, Harino S, Reinach P, Cranstoun SD, Mita S. Effects of endothelin-1 on optic nerve head blood flow in cats. J Ocul Pharmacol Ther. 1996;12:75-83. (Pubitemid 26068319)
97. Orgl S, Cioffi GA, Bacon DR, Van Buskirk EM. An endothelin- 1-induced model of chronic optic nerve ischemia in rhesus monkeys. J Glaucoma. 1996;5:135-138.
98. Orgl S, Cioffi GA, Wilson DJ, Bacon DR, Van Buskirk EM. An endothelin-1 induced model of optic nerve ischemia in the rabbit. Invest Ophthalmol Vis Sci. 1996;37:1860-1869. (Pubitemid 26265037)
99. Cioffi GA. Ischemic model of optic nerve injury. Trans Am Ophthalmol Soc. 2005;103:592-613. (Pubitemid 43042091)
100. Udono T, Takahashi K, Nakayama M et al. Induction of adrenomedullin by hypoxia in cultured retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42:1080-1086. (Pubitemid 32289807)
101. Chen B, Jiang D, Tang L. [Effects of advanced glycation end products and hypoxia on endothelin-1 secretion by bovine retinal microvascular pericytes]. Yan Ke Xue Bao. 2002;18:84-86.
102. Desai D, He S, Yorio T, Krishnamoorthy RR, Prasanna G. Hypoxia augments TNF-?alpha-mediated endothelin-1 release and cell proliferation in human optic nerve head astrocytes. Biochem Biophys Res Commun. 2004;318:642-648. (Pubitemid 38624202)
103. Prasanna G, Krishnamoorthy R, Clark AF, Wordinger RJ, Yorio T. Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci. 2002;43:2704-2713. (Pubitemid 34809463)
104. Lau J, Dang M, Hockmann K, Ball AK. Effects of acute delivery of endothelin-1 on retinal ganglion cell loss in the rat. Exp Eye Res. 2006;82:132-145. (Pubitemid 43063404)
105. Wang L, Fortune B, Cull G, Dong J, Cioffi GA. Endothelin B receptor in human glaucoma and experimentally induced optic nerve damage. Arch Ophthalmol. 2006;124:717-724.
106. Rao VR, Krishnamoorthy RR, Yorio T. Endothelin-1, endothelin A and B receptor expression and their pharmacological properties in GFAP negative human lamina cribrosa cells. Exp Eye Res. 2007;84:1115-1124. (Pubitemid 46770724)
107. Rao VR, Krishnamoorthy RR, Yorio T. Endothelin-1 mediated regulation of extracellular matrix collagens in cells of human lamina cribrosa. Exp Eye Res. 2008;86:886-894.
108. Komatsumoto S, Nara M. [Changes in the level of endothelin- 1 with aging]. Nihon Ronen Igakkai Zasshi. 1995;32: 664-669.
109. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z; EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114: 1965-1972. (Pubitemid 350016362)
110. Nouri-Mahdavi K, Hoffman D, Coleman AL et al.; Advanced Glaucoma Intervention Study. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111:1627-1635. (Pubitemid 39179673)
111. Miyauchi T, Yanagisawa M, Iida K et al. Age- and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects. Am Heart J. 1992;123:1092-1093.
112. Goodwin AT, Amrani M, Marchbank AJ, Gray CC, Jayakumar J, Yacoub MH. Coronary vasoconstriction to endothelin-1 increases with age before and after ischaemia and reperfusion. Cardiovasc Res. 1999;41:554-562. (Pubitemid 29130619)
113. Emre M, Orgl S, Haufschild T, Shaw SG, Flammer J. Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma. Br J Ophthalmol. 2005;89:60-63. (Pubitemid 40040240)
114. Nicolela MT, Ferrier SN, Morrison CA et al. Effects of coldinduced vasospasm in glaucoma: The role of endothelin-1. Invest Ophthalmol Vis Sci. 2003;44:2565-2572. (Pubitemid 36618416)
115. Henry E, Newby DE, Webb DJ, Hadoke PW, O'Brien CJ. Altered endothelin-1 vasoreactivity in patients with untreated normal-pressure glaucoma. Invest Ophthalmol Vis Sci. 2006;47:2528-2532. (Pubitemid 351639837)
116. Tunny TJ, Richardson KA, Clark CV. Association study of the 5? flanking regions of endothelial-nitric oxide synthase and endothelin-1 genes in familial primary open-angle glaucoma. Clin Exp Pharmacol Physiol. 1998;25:26-29. (Pubitemid 28064503)
117. Ishikawa K, Funayama T, Ohtake Y et al. Association between glaucoma and gene polymorphism of endothelin type A receptor. Mol Vis. 2005;11:431-437. (Pubitemid 41410236)
118. Kim SH, Kim JY, Kim DM et al. Investigations on the association between normal tension glaucoma and single nucleotide polymorphisms of the endothelin-1 and endothelin receptor genes. Mol Vis. 2006;12:1016-1021. (Pubitemid 44309183)
119. Rosenthal R, Fromm M. Endothelin antagonism as an active principle for glaucoma therapy. Br J Pharmacol. 2011;162: 806-816.
120. Polska E, Doelemeyer A, Luksch A et al. Partial antagonism of endothelin 1-induced vasoconstriction in the human choroid by topical unoprostone isopropyl. Arch Ophthalmol. 2002;120:348-352. (Pubitemid 34250057)
121. Polak K, Luksch A, Frank B, Jandrasits K, Polska E, Schmetterer L. Regulation of human retinal blood flow by endothelin-1. Exp Eye Res. 2003;76:633-640. (Pubitemid 36411938)
122. Tezel G, Kass MA, Kolker AE, Becker B, Wax MB. Plasma and aqueous humor endothelin levels in primary openangle glaucoma. J Glaucoma. 1997;6:83-89. (Pubitemid 27183191)
123. Kunimatsu S, Mayama C, Tomidokoro A, Araie M. Plasma endothelin-1 level in Japanese normal tension glaucoma patients. Curr Eye Res. 2006;31:727-731. (Pubitemid 44373544)
124. Noske W, Hensen J, Wiederholt M. Endothelin-like immunoreactivity in aqueous humor of patients with primary open-angle glaucoma and cataract. Graefes Arch Clin Exp Ophthalmol. 1997;235:551-552. (Pubitemid 27445359)
125. Iwabe S, Lamas M, Vsquez Plaez CG, Carrasco FG. Aqueous humor endothelin-1 (Et-1), vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) levels in Mexican glaucomatous patients. Curr Eye Res. 2010;35:287-294.
126. Holl G, Lakatos P, Farkas K. Cold pressor test and plasma endothelin-1 concentration in primary open-angle and capsular glaucoma. J Glaucoma. 1998;7:105-110. (Pubitemid 28196097)
127. Ghanem AA, Elewa AM, Arafa LF. Endothelin-1 and nitric oxide levels in patients with glaucoma. Ophthalmic Res. 2011;46:98-102.